OGT and prostate carcinoma: For example, studies have shown that OGT inhibition reduces cell cycle progression in a cMYC‐dependent manner in prostate cancer cells [13] and decreases epithelial–mesenchymal transition, metastasis, and invasion in vivo [14, 15].